LGND Q3 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$65M+54.9% YoY

Gross Profit

$53M82.3% margin

Operating Income

$16M24.2% margin

Net Income

$14M21.2% margin

EPS (Diluted)

$0.80

QoQ Revenue Growth

-23.4%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$462M

Stockholders' Equity

$812M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$42M	+54.9%
Gross Profit	$53M	$35M	+50.4%
Operating Income	$16M	$4M	+319.2%
Net Income	$14M	-$7M	+304.8%

Revenue Segments

Material Sales, Captisol

$35M37%

Royalty

$16M17%

Contract Revenue

$14M15%

Kyprolis

$9M9%

Milestone

$7M8%

Contract Revenue, Service

$5M5%

Royalty, Other

$4M4%

Evomela

$3M3%

License Fees, Milestones, and Product, Other, Product, Other

$2M2%

License Fees

$200,0000%